

藥物不良反應工作小組藥物安全警訊通告 107.08

歐洲藥物管理局(EMA)用藥安全資訊風險溝通:

限制攝護腺癌藥物Xofigo[®](radium-223 dichloride)之治療策略

摘要說明:

Xofigo[®]目前於衛生福利部、美國食品藥物管理署及歐洲藥物管理局之核准適應症為治療去勢抗性攝 護腺癌(castration-resistant prostate cancer)病患,其合併有症狀的骨轉移且尚未有臟器轉移者。

EMA 建議 Xofigo[®]應限制用於已經兩次治療轉移性前列腺癌(前列腺癌已經擴散到骨骼)或無法接受 其他治療之患者。

ERA-223 為隨機雙盲第三期臨床試驗,顯示與 Zytiga (abiraterone acetate)、prednisone 或 prednisolone 併用相較於安慰劑組會有增加骨折(試驗組 28.6% vs.安慰劑組 11.4%)及降低存活率(試驗組 30.7 個月 vs.安慰劑組 33.3 個月)的風險,故禁止併用。特別在有骨質疏鬆病史的骨轉移數量低病患中發生骨折 的風險較高。Xofigo[®]僅用於單一治療或與 LHRH 衍生物合併治療外,不建議同時接受其他化療。

另外,在 ALSYMPCA 隨機雙盲第三期臨床試驗中,研究結果顯示骨轉移數量低 (osteoblastic bone metastases)或 ALP <220 U/L 的病患族群在統計學上沒有顯著的臨床效益。

醫療人員注意事項:

- Xofigo[®] 禁止與 Zytiga (abiraterone acetate)、prednisone 或 prednisolone 併用。上述併用藥品最後一次服用應至少五天後再開始 Xofigo[®] 治療。
- 2) Xofigo[®]為單一治療或合併 LHRH 衍生物用於已經兩次治療轉移性前列腺癌(前列腺癌已經擴散 到骨骼)或無法接受其他治療之患者。在最後一次 Xofigo[®] 治療後至少 30 天內不應接受的全身性 癌症治療。
- 3) 骨轉移數量低的病患和僅有無症狀骨轉移的病患,不建議使用 Xofigo。。
- 4) Xofigo[®]療程開始前及治療期間應評估病患的骨質狀態(如:骨密度測量)及危險因子(如:骨質疏鬆症、骨轉移數量、併用藥物及 BMI 指數等)並提醒病患應注意的事項。應監測至少 24 個月。
- 5) 現已發現同時併用雙磷酸鹽或 denosumab 可以降低 Xofigo[®] 引起骨折的風險。
- 6) 醫療人員若懷疑病人因為使用藥品導致不良反應發生時,請立即線上通報藥物不良反應及登入於 藥物過敏/不良反應記錄中。

<u>院内品項</u>:

Xofigo[®](radium-223 dichloride) 6000 kBq/vial 鐍治骨

北醫藥物不良反應工作小組 敬啟

臨床藥學組 呂懷恩 藥師 (分機 8443/8444)



27 July 2018 EMA/500948/2018

EMA restricts use of prostate cancer medicine Xofigo

Medicine to be used only after two previous treatments or when other treatments cannot be taken

The European Medicines Agency has concluded its review of the cancer medicine Xofigo (radium-223 dichloride), and has recommended restricting its use to patients who have had two previous treatments for metastatic prostate cancer (prostate cancer that has spread to the bone) or who cannot receive other treatments.

Xofigo must also not be used with the medicines Zytiga (abiraterone acetate) and the corticosteroid prednisone or prednisolone. Xofigo should not be used with other systemic cancer therapies, except for treatments to maintain reduced levels of male hormones (hormone therapy). The medicine should also not be used in patients who have no symptoms, in line with the current indication; in addition, the use of Xofigo is not recommended in patients with a low number of bone metastases called osteoblastic bone metastases.

The review of Xofigo was carried out by EMA's Pharmacovigilance Risk Assessment Committee (PRAC) after data from a clinical study suggested that patients given Xofigo in combination with Zytiga and prednisone/prednisolone could be at risk of dying earlier and had more fractures than patients given placebo (a dummy treatment) with Zytiga and prednisone/prednisolone. The study included patients with no or only mild symptoms, whereas Xofigo is only authorised in patients with symptoms. In addition, the combination used in this study is now contraindicated. In the study, patients given the combination with Xofigo died on average 2.6 months earlier than those given the combination with placebo. In addition, 29% of patients who received the Xofigo combination had fractures, compared with 11% of patients given the placebo combination.

It is thought that Xofigo, which is taken up by the bone, accumulates at sites where the bone is already damaged, for example by osteoporosis or micro-fractures, increasing the risk of fracture. However, the reasons for a possible earlier death seen in this study are not fully understood. The company that markets Xofigo will have to conduct studies to further characterise these events and clarify the mechanisms behind them.

The PRAC's recommendations have now been endorsed by EMA's Committee for Medicinal Products for Human Use (CHMP) and will be sent to the European Commission for a final legal decision.

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact



An agency of the European Union

© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged.

Information for patients

- The prostate cancer medicine Xofigo can increase the risk of having fractures. Also, having Xofigo together with the cancer medicine Zytiga and a corticosteroid medicine (prednisone or prednisolone) for prostate cancer could possibly increase the risk of death.
- Your doctor will not use the combination of Xofigo and the other two medicines for prostate cancer. In addition Xofigo, used on its own or with medicines called 'luteinising hormone releasing hormone (LHRH) analogues', will be reserved for patients who have had at least two previous treatments for prostate cancer that has spread to the bone, or who cannot receive other treatments.
- Xofigo is authorised for use only when the spreading cancer is causing symptoms; depending on how the cancer has spread to the bone, your doctor will decide whether Xofigo is the right treatment for you.
- Before, during, and after treatment with Xofigo your doctor will carry out tests to check the health status of your bones. Depending on the results of these tests, Xofigo may be interrupted or stopped, and you may be given an alternative treatment.
- Before starting and during treatment with Xofigo, your doctor may also give you a medicine to protect your bones from fractures.
- If you experience any new or unusual bone pain or swelling before, during or after your treatment with Xofigo, you should consult your doctor.
- If you have any questions or concerns about your treatment, speak to your doctor or pharmacist.

Information for healthcare professionals

- The use of Xofigo is associated with an increased risk of fractures. A possible increased risk of death was also observed in a clinical trial investigating Xofigo in combination with abiraterone acetate and prednisone/prednisolone in patients with asymptomatic or mildly symptomatic castration-resistant prostate cancer.
- Xofigo should only be used as monotherapy or in combination with an LHRH analogue for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC), symptomatic bone metastases and no known visceral metastases, who are in progression after at least two prior lines of systemic therapy for mCRPC (other than LHRH analogues), or ineligible for any available systemic mCRPC treatment.
- Xofigo is contraindicated in combination with abiraterone acetate and prednisone/prednisolone. In addition, Xofigo should not be started in the first 5 days following the last dose of abiraterone and prednisone/prednisolone. Subsequent systemic cancer treatment should not be initiated for at least 30 days after the last administration of Xofigo.
- Xofigo is not recommended in patients with a low level of osteoblastic bone metastases and in patients with only asymptomatic bone metastases. It is also not recommended in combination with systemic cancer therapies other than LHRH analogues.
- In mildly symptomatic patients, the benefit of treatment should be carefully assessed against its risks, considering that high osteoblastic activity is likely to be required for treatment benefit (see below for more information).

- Before starting and during treatment with Xofigo, an assessment of patients' bone status (e.g. by scintigraphy, bone mineral density measurement) and risk of fractures (e.g. osteoporosis, fewer than 6 bone metastases, medication increasing fracture risk, low body mass index) should be performed. Monitoring should continue for at least 24 months.
- In patients with a high baseline risk of fracture, carefully consider the benefit of treatment against the risks.
- Concurrent use of bisphosphonates or denosumab has been found to reduce the incidence of fractures in patients treated with Xofigo. Therefore such preventive measures should be considered before starting or resuming treatment with Xofigo.

The Agency's recommendations are based on the assessment of data from a randomised, double blind, placebo controlled phase III trial (ERA-223), which showed that there was an increased incidence of fractures (28.6% vs 11.4%), a possible reduction in median overall survival (30.7 months vs 33.3 months, HR 1.195, 95% confidence interval (CI) 0.950 - 1.505, p=0.13) and an increased risk of radiological non-bone progression (HR 1.376 [95% CIs 0.972, 1.948], p=0.07) among patients receiving Xofigo in combination with abiraterone acetate plus prednisone/prednisolone (n=401) compared to patients receiving placebo in combination with abiraterone acetate plus prednisone/prednisolone (n=405). An increased fracture risk was found particularly in patients with a medical history of osteoporosis and in patients with fewer than 6 bone metastases.

In another randomised, double blind, placebo controlled phase III trial (ALSYMPCA), a statistically significant overall survival benefit of treatment with Xofigo could not be demonstrated in the subgroups of patients with fewer than 6 metastases (HR for radium-223 to placebo 0.901; 95% CI [0.553 - 1.466], p=0.674) or a baseline total alkaline phosphatase (ALP) <220 U/L (HR 0.823 95% CI 0.633- 1.068, p=0.142), indicating that efficacy may be diminished in patients with a low level of osteoblastic activity from their bone metastases.

More about the medicine

Xofigo is currently used to treat adult men with cancer of the prostate (a gland of the male reproductive system). It is authorised for use when medical or surgical castration (stopping the production of male hormones in the body using medicines or surgery) does not work, and when the cancer has spread to the bones and is causing symptoms such as pain but is not known to have spread to other internal organs.

Xofigo was authorised in the European Union in November 2013. More information on Xofigo is available on the EMA website: <u>ema.europa.eu/Find medicine/Human medicines/European public</u> <u>assessment reports</u>

More about the procedure

The review of Xofigo was initiated on 1 December 2017 at the request of the European Commission, <u>Article 20 of Regulation (EC) No 726/2004</u>.

The review was first carried out by the Pharmacovigilance Risk Assessment Committee (PRAC), the Committee responsible for the evaluation of safety issues for human medicines. In March 2018, the

PRAC recommended contraindicating the use of Xofigo with Zytiga and prednisone/prednisolone, as an interim measure, while the review was ongoing.


The final PRAC recommendations were adopted on 12 July 2018 and then sent to the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which adopted the Agency's opinion. The CHMP opinion will now be forwarded to the European Commission, which will issue a final legally binding decision applicable in all EU Member States in due course. The final stage of the review procedure is the adoption by the European Commission of a legally binding decision applicable in all EU Member States.

NIH U.S. National Library of Medicine

ClinicalTrials.gov

Find Studies ▼ About Studies ▼ Submit Studies ▼ Resources ▼ About Site ▼

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms (ERA 223)



Tracking Information	
First Submitted Date ICMJE	January 21, 2014
First Posted Date ICMJE	January 23, 2014
Last Update Posted Date	July 12, 2018
Actual Study Start Date ICMJE	March 30, 2014
Actual Primary Completion Date	February 15, 2018 (Final data collection date for primary outcome measure)
Current Primary Outcome Measures ^{ICMJE} (submitted: April 4, 2018)	Symptomatic skeletal event free survival (SSE-FS). [Time Frame: At 4 years]
Original Primary Outcome Measures ^{ICMJE} (submitted: January 21, 2014)	Symptomatic skeletal event free survival (SSE-FS) [Time Frame: At 3 years]
Change History	Complete list of historical versions of study NCT02043678 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^{ICMJE} (submitted: April 4, 2018)	 Overall Survival [Time Frame: At 4 years for interim and at 6 years for final.] Time to opiate use for cancer pain [Time Frame: At 4 years] Time to pain progression [Time Frame: At 4 years]

2018/8/20 Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate... Time to cytotoxic chemotherapy [Time Frame: At 4 years] Radiological progression free survival (rPFS) [Time Frame: At 4 years] • Number of participants with adverse events as a measure of safety and tolerability. [Time Frame: Up to 4 years] **Original Secondary Outcome** • Overall Survival [Time Frame: At 3 years for interim and at 6 years for final] Measures ICMJE (submitted: January 21, 2014) • Time to opiate use for cancer pain [Time Frame: At 3 years] Time to pain progression [Time Frame: At 3 years] Time to cytotoxic chemotherapy [Time Frame: At 3 years] • Radiological progression free survival (rPFS) [Time Frame: At 3 years] · Number of participants with adverse events as a measure of safety and tolerability [Time Frame: Up to 3 years] **Current Other Outcome** Not Provided Measures ICMJE **Original Other Outcome** Not Provided Measures ICMJE **Descriptive Information** Brief Title ICMJE Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms Official Title ICMJE A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naïve Subjects With Bone Predominant Metastatic Castrationresistant Prostate Cancer(CRPC) **Brief Summary** To determine if the addition of radium-223 dichloride to standard treatment is able to prolong life and to delay events specific for prostate cancer which has spread to the bone, such as painful fractures or bone pain which needs to be treated with an X-ray machine. **Detailed Description** This study is a phase III multinational, multicenter, randomized, double blind, placebo controlled, study with a randomization allocation ratio of 1:1 (radium-223 dichloride plus abiraterone acetate plus prednisone/prednisolone: placebo plus abiraterone acetate plus prednisone/prednisolone).The study period will consist of screening/randomization, treatment, active follow-up with clinic visits, active followup without clinic visits, and long-term follow-up phases. In this study, subjects will receive study treatment (radium-223 dichloride or placebo in addition to abiraterone acetate plus prednisone/prednisolone for the first 6 cycles followed by abiraterone acetate plus prednisone/prednisolone thereafter) until an on-study symptomatic skeletal event (SSE) occurs (or other withdrawal criteria are met). Follow-up will continue for up to 7 years or until the subject dies, is lost to followup, or withdraws informed consent and actively objects to collection of further data. This study will be conducted at approximately 150 investigative study centers and approximately 800 subjects will be enrolled. Study Type ICMJE Interventional Study Phase Phase 3 Study Design ICMJE Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

https://clinicaltrials.gov/ct2/show/record/NCT02043678

Condition ICMJE

Primary Purpose: Treatment

Prostatic Neoplasms

Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
50 kBq/kg body weight, intravenous injection (IV-slow bolus), every 4 weeks for 6 cycles. (nominal change to 55 kBq/kg after implementation of National Institute of Standards and Technology (NIST) update)
Drug: Matching placebo (normal saline)
Intravenous injection (IV-slow bolus), every 4 weeks for 6 cycles
Drug: Abiraterone
All study subjects will receive treatment with oral abiraterone acetate (1000 mg once daily),with best supportive care
Drug: Prednisone/Prednisolone
All study subjects will receive treatment with oral prednisone/prednisolone (5 mg twice daily), with best supportive care
Experimental: Radium-223 dichloride
Radium-223 dichloride +abiraterone+prednisone/prednisolone All study subjects will
receive treatment with oral abiraterone acetate (1000 mg once daily), oral
prednisone/prednisolone (5 mg twice daily), with best supportive care
 Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
 Drug: Abiraterone
Drug: Prednisone/Prednisolone
Placebo Comparator: Placebo
Placebo+abiraterone+prednisone/prednisolone All study subjects will receive treatment with oral abiraterone acetate (1000 mg once daily), oral prednisone/prednisolone (5 mg twice daily), with best supportive care
Interventions:
 Drug: Matching placebo (normal saline)
 Drug: Abiraterone
Drug: Prednisone/Prednisolone
Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information	
Recruitment Status ICMJE	Active, not recruiting
Actual Enrollment ^{ICMJE} (submitted: September 22, 2016)	806
Original Estimated Enrollment ICMJE (submitted: January 21, 2014)	800
Estimated Study Completion Date	December 23, 2019
Actual Primary Completion Date	February 15, 2018 (Final data collection date for primary outcome measure)
Eligibility Criteria ^{ICMJE}	Inclusion Criteria:

2018/8/20 Radium-223 Dichlor	ide and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate
	Histologically confirmed adenocarcinoma of the prostate
	 Male subjects of age ≥ 18 years
	 Prostate cancer progression documented by prostate specific antigen according to the Prostate Cancer Working Group 2 (PCWG2) criteria or radiological progression according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
	 Two or more bone metastases on bone scan within 4 weeks prior to randomization with no lung, liver, other visceral and/or brain metastasis.
	Asymptomatic or mildly symptomatic prostate cancer.
	 Subjects who received combined androgen blockade with an anti-androgen must have shown PSA(prostate specific antigen) progression after discontinuing the anti-androgen prior to enrollment.
	 Medical or surgical castration with testosterone less than 50 ng/dL (1.7nmol/L).
	Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
	Exclusion Criteria:
	 Prior cytotoxic chemotherapy for the treatment of CRPC, including taxanes, mitoxantrone and estramustine
	 Any chronic medical condition requiring a higher dose of corticosteroid than 5 mg prednisone/prednisolone bid.
	Pathological finding consistent with small cell carcinoma of the prostate
	 History of visceral metastasis, or presence of visceral metastasis detected by screening imaging examinations
	History of or known brain metastasis.
	Malignant lymphadenopathy exceeding 3 cm in short-axis diameter.
	 Blood transfusion or erythropoietin stimulating agents prior 4 weeks of screening and during the whole screening period before randomization
	 Imminent spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI). Subjects with history of spinal cord compression should have completely recovered
	• Use of opiate analgesics for cancer-related pain, including codeine and dextropropoxyphene, currently or anytime during the 4- week period prior to randomization.
Sex/Gender	Sexes Eligible for Study: Male
Ages	18 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers	No
Contacts ICMJE	Contact information is only displayed when the study is recruiting subjects
Listed Location Countries ICMJE	Australia, Belgium, Brazil, Canada, Finland, France, Germany, Israel, Italy, Japan, Netherlands, Norway, Poland, Russian Federation, Singapore, Spain, Sweden, United Kingdom, United States
Removed Location Countries	

Administrative Information

NCT Number ICMJE	NCT02043678
Other Study ID Numbers ICMJE	15396 2013-003438-33(EudraCT Number)
Has Data Monitoring Committee	Yes

2018/8/20

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate...

	Studies a U.S. FDA-regulated Drug Product: Yes
	Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement	Not Provided
Responsible Party	Bayer
Study Sponsor ICMJE	Bayer
Collaborators ICMJE	Janssen Research & Development, LLC
Investigators ICMJE	Study Director: Bayer Study Director Bayer
PRS Account	Bayer
Verification Date	July 2018

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

JULY 18, 2013

VOL. 369 NO. 3

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

C. Parker, S. Nilsson, D. Heinrich, S.I. Helle, J.M. O'Sullivan, S.D. Fosså, A. Chodacki, P. Wiechno, J. Logue, M. Seke,
 A. Widmark, D.C. Johannessen, P. Hoskin, D. Bottomley, N.D. James, A. Solberg, I. Syndikus, J. Kliment, S. Wedel,
 S. Boehmer, M. Dall'Oglio, L. Franzén, R. Coleman, N.J. Vogelzang, C.G. O'Bryan-Tear, K. Staudacher,
 J. Garcia-Vargas, M. Shan, Ø.S. Bruland, and O. Sartor, for the ALSYMPCA Investigators*

ABSTRACT

BACKGROUND

Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases.

METHODS

In our phase 3, randomized, double-blind, placebo-controlled study, we randomly assigned 921 patients who had received, were not eligible to receive, or declined docetaxel, in a 2:1 ratio, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matching placebo; one injection was administered every 4 weeks. In addition, all patients received the best standard of care. The primary end point was overall survival. The main secondary efficacy end points included time to the first symptomatic skeletal event and various biochemical end points. A prespecified interim analysis, conducted when 314 deaths had occurred, assessed the effect of radium-223 versus placebo on survival. An updated analysis, when 528 deaths had occurred, was performed before crossover from placebo to radium-223.

RESULTS

At the interim analysis, which involved 809 patients, radium-223, as compared with placebo, significantly improved overall survival (median, 14.0 months vs. 11.2 months; hazard ratio, 0.70; 95% confidence interval [CI], 0.55 to 0.88; two-sided P=0.002). The updated analysis involving 921 patients confirmed the radium-223 survival benefit (median, 14.9 months vs. 11.3 months; hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P<0.001). Assessments of all main secondary efficacy end points also showed a benefit of radium-233 as compared with placebo. Radium-223 was associated with low myelosuppression rates and fewer adverse events.

CONCLUSIONS

In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.)

The authors' full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Parker at the Royal Marsden Hospital, Academic Urology Unit, Downs Rd., Sutton, Surrey SM2 SPT, United Kingdom, or at chris.parker@rmh.nhs.uk.

*Additional investigators in the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) study are listed in the Supplementary Appendix, available at NEJM.org.

N Engl J Med 2013;369:213-23. DOI: 10.1056/NEJMoa1213755 Copyright © 2013 Massachusetts Medical Society.

N ENGL J MED 369;3 NEJM.ORG JULY 18, 2013

The New England Journal of Medicine

Downloaded from nejm.org at TMU AND TMU HOSPITAL on August 19, 2018. For personal use only. No other uses without permission.

ORE THAN 90% OF PATIENTS WITH metastatic castration-resistant prostate cancer have radiologic evidence of bone metastases, which are a major cause of death, disability, decreased quality of life, and increased treatment cost among these patients.^{1,2} Unlike deaths from many other types of cancer, deaths from prostate cancer are often due to bone disease and its complications.³ Current bone-targeted therapies have not been shown to improve survival, and the benefits derived from bisphosphonates, denosumab, and existing radioisotope treatments are primarily limited to pain relief and delay of skeletal events.⁴⁻¹³

Radium-223 dichloride (radium-223) is a targeted alpha emitter that selectively binds to areas of increased bone turnover in bone metastases and emits high-energy alpha particles of short range (<100 μ m).¹⁴ As a bone-seeking calcium mimetic, radium-223 is bound into newly formed bone stroma, especially within the microenvironment of osteoblastic or sclerotic metastases.^{15,16} The high-energy alpha-particle radiation induces mainly double-stranded DNA breaks that result in a potent and highly localized cytotoxic effect in the target areas.^{10,15,17,18} The short path of the alpha particles also means that toxic effects on adjacent healthy tissue and particularly the bone marrow may be minimized.^{16,19,20}

Radium-223 has been reported to have a favorable safety profile, with minimal myelotoxicity, in phase 1 and 2 studies involving patients with bone metastases.^{21,22} Phase 2 studies have shown that radium-223 reduces pain and improves disease-related biomarkers (e.g., bone alkaline phosphatase and prostate-specific antigen [PSA]),22-24 and they have suggested a survival benefit among patients with castration-resistant prostate cancer and bone metastases.²² To evaluate the effect of radium-223 on survival, we conducted the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) study, a phase 3, randomized, double-blind, multinational study comparing the efficacy and safety of radium-223 versus placebo in patients with castration-resistant prostate cancer and bone metastases.

A Quick Take animation is available at NEJM.org

METHODS

STUDY OVERSIGHT AND CONDUCT

The study was designed, conducted, and analyzed by employees of Algeta and Bayer HealthCare Pharmaceuticals, the sponsors, in collaboration with the study investigators. The blinded database was held at a third-party contract clinical research organization that provided data to the independent data and safety monitoring committee, assembled by the sponsors. After the independent data and safety monitoring committee recommended unblinding of the data, analyses were performed as defined in the statistical-analysis plan by statisticians employed by the sponsors, and the results were reviewed by the authors. The study investigators signed time-limited confidentiality agreements with the sponsors regarding publishing of the study data. Assistance in writing the first draft of the manuscript was provided by a professional medical writer paid by Bayer HealthCare Pharmaceuticals. All authors wrote the manuscript, made the decision to submit it for publication, and assume responsibility for the completeness and integrity of the data and adherence of the study to the protocol. The protocol and statistical-analysis plan are available with the full text of this article at NEJM.org.

The institutional review board at each participating center approved the study, which was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonisation.

PATIENTS

Patients were eligible to participate in the study if they had histologically confirmed, progressive castration-resistant prostate cancer with two or more bone metastases detected on skeletal scintigraphy and no known visceral metastases; were receiving the best standard of care; and had received docetaxel, were not healthy enough or declined to receive it, or it was not available. Castration-resistant disease was defined as a serum testosterone level of 50 ng per deciliter or lower $(\leq 1.7 \text{ nmol per liter})$ after bilateral orchiectomy or during maintenance treatment consisting of androgen-ablation therapy with a luteinizing hormone-releasing hormone agonist or polyestradiol phosphate. Patients with castrationresistant disease during maintenance treatment were required to continue that treatment throughout the study. Patients were required to have symptomatic disease with regular use of analgesic medication or treatment with external-beam radiation therapy required for cancerrelated bone pain within the previous 12 weeks. Additional eligibility criteria included a baseline PSA level of 5 ng per milliliter or higher with

The New England Journal of Medicine

Downloaded from nejm.org at TMU AND TMU HOSPITAL on August 19, 2018. For personal use only. No other uses without permission.

N ENGLJ MED 369;3 NEJM.ORG JULY 18, 2013

evidence of progressively increasing PSA values (two consecutive increases over the previous reference value); an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 to 2 (on a scale of 0 to 5, with 0 indicating no symptoms and full activity and higher scores indicating greater functional compromise²⁵) (see the definitions of ECOG performance-status scores in the Supplementary Appendix, available at NEJM.org); a life expectancy of 6 months or longer; and adequate hematologic, renal, and liver function.

Patients were excluded if they had received chemotherapy within the previous 4 weeks or had not recovered from adverse events due to chemotherapy. Additional exclusion criteria were previous hemibody external radiotherapy, systemic radiotherapy with radioisotopes within the previous 24 weeks, a blood transfusion or use of erythropoietin-stimulating agents within the previous 4 weeks, a malignant lymphadenopathy that was more than 3 cm in the short-axis diameter, a history of or the presence of visceral metastases, and imminent or established spinal cord compression. All patients provided written informed consent.

STUDY DESIGN AND REGIMEN

Patients were stratified according to previous use or nonuse of docetaxel, baseline alkaline phosphatase level (<220 U per liter vs. ≥220 U per liter), and current use or nonuse of a bisphosphonate. They were randomly assigned in a 2:1 ratio to receive six intravenous injections of radium-223 (at a dose of 50 kBg per kilogram of body weight) or matching placebo; one injection was administered every 4 weeks (see Fig. S1A and the description of radium-223 radiation safety in the Supplementary Appendix). The best standard of care was defined as the routine care provided at each center (e.g., local external-beam radiation therapy or treatment with glucocorticoids, antiandrogens, ketoconazole, or estrogens such as diethylstilbestrol or estramustine). Chemotherapy, hemibody external radiotherapy, and other systemic radionuclides were not permitted during the period from the first injection of the study drug to 4 weeks after the last injection of the study drug. The planned follow-up period was 3 years.

The primary end point was overall survival, defined as the time from randomization to the date of death, regardless of cause. The main secondary efficacy end points were the time to an increase in the total alkaline phosphatase level (defined as an increase of $\geq 25\%$ from baseline at

 \geq 12 weeks, in patients with no decrease from baseline, or as an increase of $\geq 25\%$ above the nadir, confirmed \geq 3 weeks later, in patients with an initial decrease from baseline), a total alkaline phosphatase response (defined as a reduction of \geq 30% from the baseline value, confirmed \geq 4 weeks later), the time to the first symptomatic skeletal event (defined as the first use of external-beam radiation therapy to relieve skeletal symptoms, new symptomatic pathologic vertebral or nonvertebral bone fractures, spinal cord compression, or tumor-related orthopedic surgical intervention), normalization of the total alkaline phosphatase level (defined as a return to a value within the normal range at 12 weeks [confirmed by two consecutive measurements ≥2 weeks apart] in patients with total alkaline phosphatase values above the upper limit of the normal range at baseline), and the time to an increase in the PSA level (defined as a relative increase of $\geq 25\%$ from the baseline level and an absolute increase of ≥ 2 ng per milliliter at ≥ 12 weeks, in patients with no decrease in the PSA level from baseline, or a relative increase of ≥25% and an absolute increase of ≥ 2 ng per milliliter above the nadir, confirmed ≥ 3 weeks later, in patients with an initial decrease from baseline). Other secondary end points included additional efficacy end points (listed in Table S1 in the Supplementary Appendix), safety end points, and quality of life.

STUDY ASSESSMENTS

Efficacy assessments included survival status, clinically evaluated symptomatic skeletal events, and total alkaline phosphatase and PSA concentrations. Safety was assessed on the basis of adverse events, hematologic values, clinical laboratory variables, and findings on electrocardiography and physical examination. All adverse events that occurred after randomization and within 12 weeks after the last injection of the study drug were reported and evaluated for their potential relationship to the study drug. Adverse events that occurred more than 12 weeks after the final injection of the study drug were reported only if they were determined to be related to the study drug by the investigator. Adverse events were graded according to the Common Terminology Criteria for Adverse Events, version 3.0 (http://ctep.cancer.gov/protocol Development/electronic_applications/docs/ctcaev3 .pdf). Quality of life was assessed with the use of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire.²⁶

The New England Journal of Medicine

Downloaded from nejm.org at TMU AND TMU HOSPITAL on August 19, 2018. For personal use only. No other uses without permission.

STATISTICAL ANALYSIS

A sample of 900 patients was required to provide a statistical power of 90% to detect a hazard ratio of 0.76 for the risk of death in the radium-223 group versus the placebo group with a two-sided alpha significance level of 0.05. The final overall survival analysis would be conducted after approximately 640 deaths had occurred. One formal interim analysis was planned after approximately 50% of the deaths (i.e., 320 deaths) had occurred, to assess the effect of radium-223 on the primary end point (overall survival). As prespecified in the protocol, the Lan–DeMets alpha spending approach²⁷ was applied with O'Brien–Fleming stopping boundaries²⁸ to evaluate the difference in overall survival between the two groups. On the basis of the actual number of deaths at the time of the interim analysis (314), a two-sided alpha significance level of 0.0028 or lower was required to support early termination of the study for efficacy. An independent data and safety monitoring committee was responsible for evaluating the results of the interim analysis. On the basis of this evaluation, which showed a survival advantage with radium-223 and an acceptable safety profile, the committee recommended early discontinuation of the trial and crossover from placebo to radium-223. We report here the results of an updated descriptive analysis of the efficacy and safety data, performed when 528 deaths had occurred, before any crossover treatment with radium-223 was administered.

Table 1. Baseline Characteristics of the Patients.*		
Characteristic	Radium-223 (N = 614)	Placebo (N = 307)
Age		
Median (range) — yr	71 (49–90)	71 (44–94)
>75 yr — no. (%)	171 (28)	90 (29)
White race — no. (%)†	575 (94)	290 (94)
Total alkaline phosphatase — no. (%)		
<220 U/liter	348 (57)	169 (55)
≥220 U/liter	266 (43)	138 (45)
Current use of bisphosphonates — no. (%)		
Yes	250 (41)	124 (40)
No	364 (59)	183 (60)
Any previous use of docetaxel — no. (%)		
Yes	352 (57)	174 (57)
No	262 (43)	133 (43)
ECOG performance-status score — no. (%) \ddagger		
0	165 (27)	78 (25)
1	371 (60)	187 (61)
≥2	77 (13)	41 (13)
WHO ladder for cancer pain — no. (%) $ rbrace$		
1	257 (42)	137 (45)
2	151 (25)	78 (25)
3	194 (32)	90 (29)
Extent of disease — no. (%)		
<6 metastases	100 (16)	38 (12)
6–20 metastases	262 (43)	147 (48)
>20 metastases	195 (32)	91 (30)
Superscan¶	54 (9)	30 (10)

N ENGLJ MED 369;3 NEJM.ORG JULY 18, 2013

The New England Journal of Medicine

Downloaded from nejm.org at TMU AND TMU HOSPITAL on August 19, 2018. For personal use only. No other uses without permission.

Table 1. (Continued.)		
Characteristic	Radium-223 (N=614)	Placebo (N = 307)
External-beam radiation therapy within 12 wk after screening — no. (%)		
Yes	99 (16)	48 (16)
No	515 (84)	259 (84)
Median biochemical values (range)		
Hemoglobin — g/dl	12.2 (8.5–15.7)	12.1 (8.5–16.4)
Albumin — g/liter	40 (24–53)	40 (23–50)
Total alkaline phosphatase — U/liter	211 (32–6431)	223 (29–4805)
Lactate dehydrogenase — U/liter	315 (76–2171)	336 (132–3856)
$PSA - \mu g/liter$	146 (3.8–6026)	173 (1.5–14500)

* Percentages may not sum to 100 due to rounding.

† Race was self-reported.

The Eastern Cooperative Oncology Group (ECOG) scores the performance status of patients with respect to activities of daily living as follows: 0, fully active and able to carry out all predisease activities without restriction; 1, restricted in physically strenuous activity but ambulatory and able to carry out work of a light nature; 2, ambulatory and up and about for more than 50% of waking hours and capable of self-care but unable to carry out work activities; 3, capable of only limited self-care and confined to a bed or chair for more than 50% of waking hours; 4, completely disabled; and 5, dead.

§ A total of 12 patients in the radium-223 group (2%) and 2 patients in the placebo group (1%) had no pain or analgesic use at baseline. A World Health Organization (WHO) score of 1 indicates mild pain and no opioid use, 2 indicates moderate pain and occasional opioid use, and 3 indicates severe pain and regular daily opioid use.

¶ Superscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without renal and background activity.

The normal ranges are as follows: hemoglobin, 13.4 to 17.0 g per deciliter; albumin, 36 to 45 g per liter; total alkaline phosphatase, 35 to 105 U per liter; lactate dehydrogenase, 115 to 255 U per liter; and prostate-specific antigen (PSA), 0 to 3.999 μ g per liter.

The stratified log-rank test was used as the primary analysis for survival; subgroup analyses were performed to assess whether the treatment effect was consistent across subgroups. The main secondary efficacy end points were analyzed with the use of a gatekeeping procedure to control for the overall type I error rate; an end point was tested at a two-sided significance level of 0.05 only if the two-sided P value for all higher-ranking end points was 0.05 or lower. The intention-to-treat population included all randomly assigned patients, and the safety population was composed of patients who received at least one injection of a study drug.

After unblinding of the data, inconsistencies were noted between the total number of symptomatic skeletal events as reported on the casereport form and the number in the listings of adverse events. Thus, a post hoc sensitivity analysis was performed after resolution of these inconsistencies with the study sites. As shown in Figure S2 and Table S2 in the Supplementary Appendix, these inconsistencies did not affect the results of the original analysis to any meaningful degree.

RESULTS


PATIENTS AND STUDY REGIMEN

From June 2008 through February 2011, a total of 921 patients were enrolled (614 in the radium-223 group and 307 in the placebo group) at 136 study centers in 19 countries and were included in the intention-to-treat population (Fig. S1B in the Supplementary Appendix). The safety population included 901 patients (600 in the radium-223 group and 301 in the placebo group). Baseline clinical and demographic characteristics were well balanced between the study groups (Table 1). The planned interim analysis was based on data from 809 enrolled patients (541 in the radium-223 group and 268 in the placebo group) (Table S3 in the Supplementary Appendix).

Overall, as of this writing, 532 of 921 patients (58%) had received all six injections of the study drug (387 patients in the radium-223 group [63%] and 145 in the placebo group [47%]). The median number of injections was six in the radium-223 group and five in the placebo group.

The New England Journal of Medicine

Downloaded from nejm.org at TMU AND TMU HOSPITAL on August 19, 2018. For personal use only. No other uses without permission.



to the First Symptomatic Skeletal Event.

EFFICACY

At the interim analysis, the median overall survival was 14.0 months in the radium-223 group and 11.2 months in the placebo group (Fig. S3A in the Supplementary Appendix). Radium-223, as compared with placebo, was associated with a 30% reduction in the risk of death (hazard ratio, 0.70; 95% confidence interval [CI], 0.55 to 0.88; two-sided P=0.002). In the intention-to-treat population, 314 patients died. In the radium-223 group, 191 of 541 patients died (35%), and in the placebo group, 123 of 268 patients died (46%). The effect of radium-223 on overall survival was consistent across all subgroups (Fig. S3B in the Supplementary Appendix), and radium-223, as compared with

placebo, was not associated with significantly more grade 3 or 4 toxic effects (Table S4 in the Supplementary Appendix). On the basis of these data, the independent data and safety monitoring committee recommended termination of the trial.

In the updated analysis, the median overall survival was 14.9 months in the radium-223 group and 11.3 months in the placebo group (Fig. 1A). The updated analysis confirmed the 30% reduction in the risk of death among patients in the radium-223 group as compared with the placebo group (hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P<0.001). A total of 528 patients in the intention-to-treat population died. In the radium-223 group, 333 of 614 patients died (54%), and in the placebo group, 195 of 307 patients died (64%). The effect of radium-223 on overall survival was consistent across all subgroups (Fig. 2).

All main secondary efficacy end points provided support for the benefit of radium-223 plus the best standard of care over placebo plus the best standard of care (Table 2). Radium-223, as compared with placebo, significantly prolonged the time to the first symptomatic skeletal event (median, 15.6 months vs. 9.8 months; hazard ratio, 0.66; 95% CI, 0.52 to 0.83; P<0.001) (Fig. 1B), the time to an increase in the total alkaline phosphatase level (hazard ratio, 0.17; 95% CI, 0.13 to 0.22; P<0.001) (Fig. S4A in the Supplementary Appendix), and the time to an increase in the PSA level (hazard ratio, 0.64; 95% CI, 0.54 to 0.77; P<0.001) (Fig. S4B in the Supplementary Appendix). Increases in the alkaline phosphatase and PSA levels, as defined in the protocol, were assessed after 12 weeks; a post hoc analysis of alkaline phosphatase and PSA levels from the start of study-drug administration is shown in Figure S4C and S4D in the Supplementary Appendix, respectively. In addition, a significantly higher proportion of patients in the radium-223 group than in the placebo group had a response according to the total alkaline phosphatase level (≥30% reduction, P<0.001) and normalization of this level (P<0.001). A 30% or greater reduction in PSA blood levels at week 12 was achieved in 16% of patients in the radium-223 group and in 6% of patients in the placebo group (P<0.001). This reduction was sustained 4 weeks after the last injection in 14% of patients in the radium-223 group and in 4% of patients in the placebo group (P<0.001).

N ENGLJ MED 369;3 NEJM.ORG JULY 18, 2013

The New England Journal of Medicine

Downloaded from nejm.org at TMU AND TMU HOSPITAL on August 19, 2018. For personal use only. No other uses without permission.

Subgroup	Radium-223	Placebo	Radium-223	Placebo	Hazard Ratio (95	5% CI)
Subgroup	no. of pa		median overall		•	,,,, c ,,
All patients	614	307	14.9	11.3	⊢ <u></u> −−−− [†]	0.70 (0.58–0.83)
, Total ALP level at baseline						· · · ·
<220 U/liter	348	169	17.0	15.8		0.82 (0.64-1.07)
≥220 U/liter	266	138	11.4	8.1		0.62 (0.49–0.79)
, Current bisphosphonate use						· · · ·
Yes	250	124	15.3	11.5		0.70 (0.52-0.93)
No	364	183	14.5	11.0		0.74 (0.59–0.92)
Previous docetaxel use						· · · ·
Yes	352	174	14.4	11.3		0.71 (0.56-0.89)
No	262	133	16.1	11.5		0.74 (0.56–0.99)
Baseline ECOG performance-status	score					(<i>'</i>
0 or 1	536	265	15.4	11.9		0.68 (0.56-0.82)
≥2	77	41	10.0	8.4		0.82 (0.50-1.35)
Extent of disease						· · · ·
<6 metastases	100	38	27.0	NE	►	0.95 (0.46-1.95)
6–20 metastases	262	147	13.7	11.6		0.71 (0.54–0.92)
>20 metastases	195	91	12.5	9.1		0.64 (0.47-0.88)
Superscan	54	30	11.3	7.1		0.71 (0.40-1.27)
Opioid use						· · · ·
Yes	345	168	13.9	10.4		0.68 (0.54-0.86)
Νο	269	139	16.4	12.8		0.70 (0.52-0.93)
					0.5 1.0	2.0
					•	2.0
					Radium-223 Placebo Better Better	

Figure 2. Subgroup Analysis of Hazard Ratios for Death in the Two Study Groups.

The Eastern Cooperative Oncology Group (ECOG) scores the performance status of patients with respect to activities of daily living as follows: 0, fully active and able to carry out all predisease activities without restriction; 1, restricted in physically strenuous activity but ambulatory and able to carry out work of a light nature; 2, ambulatory and up and about for more than 50% of waking hours and capable of self-care but unable to carry out work activities; 3, capable of only limited self-care and confined to a bed or chair for more than 50% of waking hours; 4, completely disabled; and 5, dead. The category for use of opioids includes patients with a score of 2 or 3 on the World Health Organization "ladder" for cancer pain (a score of 1 indicates mild pain and no opioid use, 2 indicates moderate pain and occasional opioid use, and 3 indicates severe pain and regular daily opioid use). The category for nonuse of opioids includes patients without pain or opioid use at baseline and patients with a score of 1 on the WHO ladder for cancer pain. Superscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without renal and background activity. ALP denotes alkaline phosphatase, and NE not evaluated.

SAFETY

The number of patients who had adverse events after they received the study drug was consistently lower in the radium-223 group than in the placebo group for all adverse events (558 of 600 patients [93%] vs. 290 of 301 patients [96%]), grade 3 or 4 adverse events (339 patients [56%] vs. 188 patients [62%]), serious adverse events (281 patients [47%] vs. 181 patients [60%]), and studydrug discontinuation because of adverse events (99 patients [16%] vs. 62 patients [21%]).

Hematologic and nonhematologic adverse events that occurred in at least 5% of patients in either study group are shown in Table 3. Overall, no clinically meaningful differences in the frequency of grade 3 or 4 adverse events were observed between the study groups. Grade 3 febrile neutropenia was reported in one patient (<1%) in the radium-223 group and in one patient (<1%) in the placebo group. Only one grade 5 hematologic adverse event was considered to be possibly related to the study drug: thrombocytopenia in a patient in the radium-223 group, who died from pneumonia with hypoxemia, with no evidence of bleeding. For serious adverse events that occurred in at least 5% of patients in the radium-223 group or the placebo group, the respective frequencies were as follows: disease progression (11% and 12%), bone pain (10% and 16%), anemia (8% and 9%), and spinal cord compression (4% and 5%).

A significantly higher percentage of patients who received radium-223, as compared with those

219

The New England Journal of Medicine

Downloaded from nejm.org at TMU AND TMU HOSPITAL on August 19, 2018. For personal use only. No other uses without permission.

End Point	Radium-223 (N = 614)	Placebo (N = 307)	Hazard Ratio (95% CI)	P Value
Median time to first symptomatic skeletal event — mo	15.6	9.8	0.66 (0.52–0.83)	<0.001
Median time to increase in total alkaline phosphatase level — mo	7.4	3.8	0.17 (0.13–0.22)	<0.001
Median time to increase in PSA level — mo	3.6	3.4	0.64 (0.54–0.77)	<0.001
Patients with ≥30% reduction in total alkaline phospha- tase response — no. /total no. (%)	233/497 (47)	7/211 (3)		<0.001
Patients with normalization of total alkaline phospha- tase level — no./total no. (%)*	109/321 (34)	2/140 (1)		<0.001

* Only patients who had elevated total alkaline phosphatase levels at baseline are included.

who received placebo, had a meaningful improvement in the quality of life according to the FACT-P total score (i.e., an increase in the score of ≥ 10 points on a scale of 0 to 156, with higher scores indicating a better overall quality of life) during the period of study-drug administration (25% vs. 16%, P=0.02). The mean change in the FACT-P total score from baseline to week 16 significantly favored the radium-223 group, as compared with the placebo group (-2.7 vs. -6.8, P=0.006).

DISCUSSION

In this phase 3 study, radium-223 significantly prolonged overall survival in patients who had castration-resistant prostate cancer and bone metastases, with a 30% reduction in the risk of death, as compared with placebo. In the updated analysis, the median survival was longer among patients who received radium-223 than among those who received placebo, by 3.6 months. All main secondary efficacy end points were significant and favored treatment with radium-223, including the clinically defined end point of the time to the first symptomatic skeletal event, which was significantly prolonged among patients who received radium-223. Whereas other trials included asymptomatic fractures — detected by means of periodic radiologic review - as skeletal events, in this study, only symptomatic pathologic bone fractures were included as symptomatic skeletal events.

The highly targeted nature of radium-223, with alpha particles of short range (<100 μ m), mini-

mizes myelosuppression and has limited effects on normal tissue. The overall incidence of adverse events was consistently lower in the radium-223 group than in the placebo group for adverse events of all grades, grade 3 or 4 adverse events, and serious adverse events. The number of patients who discontinued the study drug because of adverse events was also lower in the radium-223 group. No clinically meaningful differences in the frequency of hematologic adverse events were observed between the study groups.

A distinctive feature of the study was the liberal definition of the best standard of care permitted with both study drugs (radium-223 and placebo); this allowed patients to be treated with standard therapies chosen by the treating physician. Consequently, findings from this study may be generalizable to routine clinical practice, since the control group consisted of patients who received placebo with the best standard of care. The study also has high external validity because it used liberal inclusion criteria that are representative of the general population of patients with castration-resistant prostate cancer. One limitation was the exclusion of patients with visceral metastases, which may occur in up to 25% of patients with castration-resistant prostate cancer.1,29

Many patients with castration-resistant prostate cancer and bone metastases do not receive docetaxel because they are too frail (ECOG performance-status score >2), they have coexisting conditions that preclude its use, or they simply decline treatment. Our study addressed this important group by including patients who were not

N ENGLJ MED 369;3 NEJM.ORG JULY 18, 2013

The New England Journal of Medicine

Downloaded from nejm.org at TMU AND TMU HOSPITAL on August 19, 2018. For personal use only. No other uses without permission.

Adverse Event	Radium-223 (N = 600)				Placebo (N = 301)				
	All Grades	Grade 3	Grade 4	Grade 5*	All Grades	Grade 3	Grade 4	Grade 5*	
				number of pa	tients (percent)				
Hematologic									
Anemia	187 (31)	65 (11)	11 (2)	0	92 (31)	37 (12)	2 (1)	1 (<1)	
Thrombocytopenia	69 (12)	20 (3)	18 (3)	1 (<1)	17 (6)	5 (2)	1 (<1)	0	
Neutropenia	30 (5)	9 (2)	4 (1)	0	3 (1)	2 (1)	0	0	
Nonhematologic									
Constipation	108 (18)	6 (1)	0	0	64 (21)	4 (1)	0	0	
Diarrhea	151 (25)	9 (2)	0	0	45 (15)	5 (2)	0	0	
Nausea	213 (36)	10 (2)	0	0	104 (35)	5 (2)	0	0	
Vomiting	111 (18)	10 (2)	0	0	41 (14)	7 (2)	0	0	
Asthenia	35 (6)	5 (1)	0	0	18 (6)	4 (1)	0	0	
Fatigue	154 (26)	21 (4)	3 (1)	0	77 (26)	16 (5)	2 (1)	0	
Deterioration in general physical health	27 (4)	9 (2)	2 (<1)	5 (1)	21 (7)	8 (3)	2 (1)	2 (1)	
Peripheral edema	76 (13)	10 (2)	0	0	30 (10)	3 (1)	1 (<1)	0	
Pyrexia	38 (6)	3 (1)	0	0	19 (6)	3 (1)	0	0	
Pneumonia	18 (3)	9 (2)	0	4 (1)	16 (5)	5 (2)	2 (1)	0	
Urinary tract infection	47 (8)	7 (1)	0	0	28 (9)	4 (1)	1 (<1)	1 (<1)	
Weight loss	69 (12)	4 (1)	0	0	44 (15)	5 (2)	0	0	
Anorexia	102 (17)	9 (2)	0	0	55 (18)	2 (1)	0	0	
Decreased appetite	35 (6)	2 (<1)	0	0	13 (4)	0	0	0	
Bone pain	300 (50)	120 (20)	5 (1)	0	187 (62)	74 (25)	3 (1)	0	
Muscular weakness	9 (2)	2 (<1)	1 (<1)	0	17 (6)	6 (2)	0	0	
Pathologic fracture	22 (4)	13 (2)	0	0	15 (5)	8 (3)	1 (<1)	0	
Progression of malignant neoplasm	77 (13)	9 (2)	4 (1)	55 (9)	44 (15)	4 (1)	1 (<1)	33 (11)	
Dizziness	43 (7)	2 (<1)	0	0	26 (9)	2 (1)	0	0	
Spinal cord compression	25 (4)	14 (2)	6 (1)	1 (<1)	23 (8)	16 (5)	1 (<1)	0	
Insomnia	27 (4)	0	0	0	21 (7)	l (<l)< td=""><td>0</td><td>0</td></l)<>	0	0	
Hematuria	30 (5)	7 (1)	0	0	15 (5)	3 (1)	0	0	
Urinary retention	25 (4)	9 (2)	0	0	18 (6)	6 (2)	0	0	
Dyspnea	49 (8)	10 (2)	1 (<1)	1 (<1)	26 (9)	7 (2)	0	3 (1)	

* Only one grade 5 hematologic adverse event was considered to be possibly related to the study drug: thrombocytopenia in one patient in the radium-223 group.

thought to be eligible to receive chemotherapy or study addresses an important unmet need in a who chose not to receive it. It is possible that some of these men could have received chemotherapy at other institutions or in other studies; however, at least 20 to 40% of patients with castration-resistant prostate cancer and bone metastases never receive chemotherapy,³⁰⁻³² so our

population that is not served by current therapies.

The treatment of prostate cancer has evolved since the trial began, with new data on the use of cabazitaxel,29 abiraterone,33 and enzalutamide34 in patients who have received docetaxel. The excellent safety profile of radium-223 and the nonover-

N ENGLJ MED 369;3 NEJM.ORG JULY 18, 2013

The New England Journal of Medicine

Downloaded from nejm.org at TMU AND TMU HOSPITAL on August 19, 2018. For personal use only. No other uses without permission.

lapping mechanism of action make radium-223 potentially suitable for use either sequentially or in combination with these other agents. A phase 1–2 trial of radium-223 combined with docetaxel in patients with castration-resistant prostate cancer and bone metastases is currently ongoing (ClinicalTrials.gov number, NCT01106352).

Presented in part at the European Multidisciplinary Cancer Congress, Stockholm, September 23–27, 2011; the Genitourinary Cancers Symposium, San Francisco, February 2–4, 2012; 27th Annual Congress of the European Association of Urology, Paris, February 24–28, 2012; annual meeting of the American Urological Association, Atlanta, May 19–23, 2012; annual meeting of the American Society of Clinical Oncology, Chicago, June 1–5, 2012; and the European Society for Medical Oncology Congress, Vienna, September 28–October 2, 2012.

Supported by Algeta and Bayer HealthCare Pharmaceuticals. Dr. Parker reports receiving consulting and lecture fees from Amgen, Astellas, Bayer, and Janssen, consulting fees from Bristol-Myers Squibb, BN ImmunoTherapeutics, and Takeda, and lecture fees from Sanofi-Aventis; Dr. Nilsson reports serving as an advisory board member for Algeta; Dr. Heinrich reports receiving lecture fees from Bayer, Sanofi-Aventis, Pfizer, and Novartis, payment for the development of educational presentations from Bayer and travel support from Bayer, Sanofi-Aventis, Pfizer, Novartis, and GlaxoSmithKline; Dr. Fosså reports serving as a board member for Bristol-Myers Squibb and receiving consulting and lecture fees from Amgen, Sanofi, and Janssen-Cilag; Dr. Widmark reports serving as a board member and receiving lecture fees from Astellas, and being employed by Sanofi; Dr. James reports receiving consulting fees from Janssen, Sanofi, Medivation, Bayer, and Pierre Fabre, receiving grant support through his institution from Pfizer, Sanofi, Novartis, Amgen, Bayer, Astellas, Janssen, and GlaxoSmithKline, receiving lecture fees from Sanofi, Pierre Fabre, Amgen, and Janssen, and travel support from Sanofi and Ferring; Dr. Wedel reports receiving consulting fees from Roche and Sanofi-Aventis, payment for the development of educational presentations from Roche, Amgen, and Sanofi-Aventis, and travel support from Sanofi-Aventis, Janssen, Roche, and Pfizer; Dr. Dall'Oglio reports serving as a board member and receiving consulting fees from Debiopharm, serving as an unpaid consultant to Ferring Pharmaceuticals, receiving grant support through his institution from GlaxoSmith-Kline and Novartis Biociências, and receiving lecture fees from AstraZeneca; Dr. Coleman reports receiving consulting and lecture fees from Amgen and providing expert testimony for Novartis in cases regarding the development of osteonecrosis of the jaw associated with use of zoledronic acid, a Novartis product; Dr. Vogelzang reports receiving consulting fees from Dendreon, Sanofi-Aventis, Amgen, and Novartis, consulting and lecture fees from Johnson & Johnson, and lecture fees and payment for the development of educational presentations from Astellas; Dr. O'Bryan-Tear and Ms. Staudacher report being employees of and holding stock in Algeta; Dr. Garcia-Vargas reports being an employee of Bayer; Dr. Shan reports being an employee of and holding stock in Bayer; Dr. Bruland reports serving as a board member for and holding stock in Algeta, being a co-inventor on U.S. patent number 6,635,234 B1 regarding Alpharadin, which is owned by Algeta, and receiving lecture fees from Novartis and Amgen; and Dr. Sartor reports receiving consulting fees from Aragon, Astellas, Bavarian Nordic, Bellicum, Dendreon, Medivation, OncoGeneX, and Pfizer, consulting fees and grant support through his institution from Johnson & Johnson and Sanofi-Aventis, and grant support through his institution from Algeta, Bayer, and Takeda. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank the patients who volunteered to participate in this study; the study center staff members who cared for them; the members of the independent data and safety monitoring committee: Dr. Luis Paz-Arez (oncologist and chairperson), Dr. John Buscombe (nuclear medicine specialist), Dr. Ian Ford (biostatistician), Dr. Kurt Miller (urologist), and Dr. Saad Shakir (pharmacovigilance expert); the sponsor staff involved in data collection and analyses: Hayley Robb and Andy Cross (PharmaNet); the sponsor staff involved in the conduct of the trial: Irene Skjørestad, Marianne Fugli, and Trine Jensen (Algeta); and Heather Nyce, Ph.D. (SciStrategy Communications), for medical writing assistance.

APPENDIX

The authors' full names, academic degrees, and affiliations are as follows: Royal Marsden National Health Service Foundation Trust and Institute of Cancer Research, Sutton (Christopher Parker, M.D.), Centre for Cancer Research and Cell Biology, Queen's University, Belfast (Joe M. O'Sullivan, M.D.), Christie Hospital, Manchester (John Logue, F.R.C.R.), Mount Vernon Hospital Cancer Centre, Northwood (Peter Hoskin, M.D.), St. James's University Hospital, Leeds (David Bottomley, F.R.C.R.), Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, Birmingham (Nicholas D. James, M.D., Ph.D.), Clatterbridge Center for Oncology, Wirral (Isabel Syndikus, F.R.C.R.), and Weston Park Hospital, Sheffield (Robert Coleman, M.D.) - all in the United Kingdom; Karolinska University Hospital, Stockholm (Sten Nilsson, M.D., Ph.D.), Centrallasarettet Växjö, Växjö (Mihalj Seke, M.D.), Umeå University (Anders Widmark, M.D., Ph.D.) and Umeå University Hospital (Lars Franzén, M.D., Ph.D.), Umeå, and Länssjukhuset Sundsvall-Härnösand County Hospital, Sundsvall (L.F.) — all in Sweden; Akershus University Hospital, Lørenskog (Daniel Heinrich, M.D.), Haukeland University Hospital, Bergen (Svein Inge Helle, M.D., Ph.D.), Radiumhospitalet (Sophie D. Fosså, M.D., Ph.D.), Ullevål University Hospital (Dag Clement Johannessen, M.D.), Algeta (Charles Gillies O'Bryan-Tear, M.R.C.P., Karin Staudacher, M.Sc.), and Norwegian Radium Hospital and Faculty of Medicine, University of Oslo (Øyvind S. Bruland, M.D., Ph.D.), Oslo, and St. Olavs Hospital, Trondheim (Arne Solberg, M.D., Ph.D.) — all in Norway; Hospital Kochova, Chomutov, Czech Republic (Aleš Chodacki, M.D.); Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland (Paweł Wiechno, M.D., Ph.D.); Jessenius School of Medicine, University Hospital, Martin, Slovakia (Jan Kliment, M.D.); Ortenau Klinikum Offenburg-Gengenbach, Klinik für Urologie und Kinderurologie, Offenburg (Steffen Wedel, M.D.), and Gemeinschaftspraxis, Berlin (Sibylle Boehmer, Dipl.Med.) - both in Germany; Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Instituto do Câncer do Estado de São Paulo, São Paulo (Marcos Dall'Oglio, M.D., Ph.D.); Comprehensive Cancer Centers of Nevada, Las Vegas (Nicholas J. Vogelzang, M.D.); Bayer HealthCare Pharmaceuticals, Montville, NJ (Jose Garcia-Vargas, M.D., Minghua Shan, Ph.D.); and Tulane Cancer Center, New Orleans (Oliver Sartor, M.D.).

The New England Journal of Medicine

Downloaded from nejm.org at TMU AND TMU HOSPITAL on August 19, 2018. For personal use only. No other uses without permission.

REFERENCES

 Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
 Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.

3. Lange PH, Vessella RL. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev 1998-1999;17:331-6.

4. Lipton A. Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol 2010;37:Suppl 2:S15-S29.

 Adami S. Bisphosphonates in prostate carcinoma. Cancer 1997;80:Suppl:1674-9.
 Silberstein EB. Systemic radiopharmaceutical therapy of painful osteoblastic metastases. Semin Radiat Oncol 2000;10: 240-9.

7. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-71.

8. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet 2011; 377:813-22.

9. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005;6:392-400.

10. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med 2005;46: Suppl 1:38S-47S.

11. Sartor O. Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer. Asian J Androl 2011;13:366-8.

12. Sartor O, Bruland O. Stromal targeted therapies in prostate and renal cancer: new concepts and knowledge. Clin Genitourin Cancer 2011;9:1-2.

13. Sartor O, Goeckeler W, Bruland O. Stromal targeted therapy in bone metastatic prostate cancer: promise delivered. Asian J Androl 2011;13:783-4.

14. Bruland ØS, Nilsson S, Fisher DR,

Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 2006;12:6250s-6257s.

15. Henriksen G, Breistøl K, Bruland \emptyset S, Fodstad \emptyset , Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002;62:3120-5.

16. Henriksen G, Fisher DR, Roeske JC, Bruland ØS, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med 2003;44:252-9.

17. Liepe K. Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer. Curr Opin Investig Drugs 2009;10:1346-58.

18. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998;25: 1341-51.

19. Kerr C. (223)Ra targets skeletal metastases and spares normal tissue. Lancet Oncol 2002;3:453.

20. Li Y, Russell PJ, Allen BJ. Targeted alpha-therapy for control of micrometastatic prostate cancer. Expert Rev Anticancer Ther 2004;4:459-68.

21. Nilsson S, Larsen RH, Fosså SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11: 4451-9.

22. Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8:587-94.
23. Parker CC, Pascoe S, Chodacki A, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra-223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 2013;63:189-97.

24. Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012;48:678-86. **25.** Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.

26. Cella D, Nichol MB, Eton D, et al. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy–Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health 2009;12:124-9.

27. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.

28. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.

29. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54.

30. Perlroth DJ, Thompson SF, Luna Y, et al. Timing is everything: time to ADT and chemotherapy initiation for treatment of metastatic prostate cancer (mPC). Presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium, San Francisco, February 2–4, 2012 (poster).
31. Perlroth DJ, Thompson SF, Mozaffari E, et al. Treating people right: who goes untreated with systemic therapy for metastatic prostate cancer (mPC)? Presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium, San Francisco, February 2–4, 2012 (poster).

32. Harris V, Lloyd K, Forsey S, Rogers P, Roche M, Parker C. A population-based study of prostate cancer chemotherapy. Clin Oncol (R Coll Radiol) 2011;23:706-8.
33. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.

34. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.

Copyright © 2013 Massachusetts Medical Society.

POSTING PRESENTATIONS FROM MEDICAL MEETINGS ONLINE

Online posting of an audio or video recording of an oral presentation at a medical meeting, with selected slides from the presentation, is not considered prior publication. Authors should feel free to call or send e-mail to the *Journal*'s Editorial Offices if there are any questions about this policy.

223

The New England Journal of Medicine

Downloaded from nejm.org at TMU AND TMU HOSPITAL on August 19, 2018. For personal use only. No other uses without permission.



1 藤島名輝 结治骨部注射治


2. 組成

於參照日期時,每mL溶液含有1100 kBg鑄-223二氯化物(Radium-223 dichloride),相當於含0.58 mg鎬-223。鎬以游離雄子的形式存在

林滨海中 每小瓶含有6mL溶液(结-223二氯化物於条照日期為6.6 MBg)

每.233点46百元44 · 麦麦加 有11 4天, 它若定类自15480m(g)。 每.233460万元66代表型 · 麦克加 有11 4天, 它若定类自15480m(g)。 每.233460.27006代表型 · 曼金建算系子代表的Manh(g)。並用每不可能量含手的3.0% (卡均能量40.445 MeV和0.492 MeV), 可我相对 本学的能量含+和695.3% (金素提高50.5.75 MeV), 或相對称于的能量含手的3.0% (卡均能量40.445 MeV和0.492 MeV),可我相对 本学的能量含+和615% (金素提高50.5.75 MeV)。

圖1: 鐳-223衰變鏈、自然半衰期及衰變模式:



财形利 每mL溶液含有0.194 mmol (相當於4.5 ng)的夠

完整的赋形劑,请参阅第6.1節

²⁰⁷Pb stable

3. 劑型

Bayer

🕡 Xofigo

注射液劑 澄清、無色的等參透壓溶液,嚴鹼值(5H)介於6.0和8.0間,

4. 臨床特性

4.1 治療道應症

4.1 @ 第-4084. 本品用於治療去勞抗性攝護除癌(castration-resistant prostate cancer)病人,其合併有症狀的骨轉移工尚未有臟器轉移者。 4.2 劍量與給藥方式 "A MILY 10 # // (請參問第6,4) (請參問第6,6節)進行給藥

利量 Xofigo的劑量發送為每公斤體事給予55kBa的放射活性,每隔4週給予,共6劑注於。

商未針對注射Xcfigo超過6前的安全性與療效進行研究 計算給藥體積的詳細說明請參問第8節。

者年病人

○ Trim請試驗約600位以Xofig:治療結病人中,447在病人(74.5%)為65歲以上,同时196在病人(22.7%)為75歲以上。 在第III期試驗中,並未聽察到老年病人(年龄≥65歲)和平徑病人(年龄<65歲)的安全性及療放育烹體上的差異。老年病人不認為需要,調整預量。</p> 肝功能不全病人

》勿認力至於入 每未值打的能受損傷人中針對Xofigo切安全性及應效進行過試驗。 由於歸之23號不是由許擴代謝,也不是越由證計將除,因此並不預新計功能受損會影響到氧化緯223的蘇動學。 認為在打力流使損成人中壽雪繁發者。 **臀功能不全病人**

在第111前临底以渝中,在根度量功能受损(UR截开廓清率(CLCR):50至80mlmin)商导功能工作均共同,重表起客则完全性或能效的 有關處果,在中党(CLCR:50至50mlmin)委变度(CLCR:50至80mlmin)劳动使受损病人中的资料消化。並承承期高小的相關資料。 成而,由功采成为利用器量,工具是利益定使是取組成後,因是特加能受性前期不管影響最优化2250%数量。 認為在肾功能受損病人中無需調整劑量

ヘエペリ 南未在兌量和18歲以下青少年中針對Xofigo的安全性與療效進行研究。在攝護障癌道應症中,本藥品並無相關使用於兒童挨群中。

用水缸之業。1000(1)用/1110/1000(0)及上戶2%以來(1)110、如用水水量量加), 用水量量 <u>基度方式</u> Xafigozif 和定止接, 必須以建優注射(還常為1)分泌(6)式於最。 Xafigozif 和定止接, 必須以等於起感的進化的mp(mL(0.9%)注射用溶液沖洗靜脈輸注管路支導管, 屬於使用未構品的面片說明, #拿因落6.6和系称。

43 禁忌症

4.5 示心症 Xofigo的使用上並無已知的禁忌症 4.4 特殊警語與使用注意事項

至鐵環鏡 按幾250回公准約弱人中曾有骨髓抑制的通報,特別是血小板減少症、喘中性白血球減少症、亡血球減少症及全血球減少症(請參閱 第43回)。

第4-5a0), Q武,必须在基期及何一個Xofigo治療前對病人進行血液學評估。第1次給藥前,絕對噴中性白血综計数(ANC)應≥1.5 x 10%1、血小 极計数2 100 x 11%1点電話案2 10.0 g/d = 面後,後截這時給藥劑,ANC應2 1.0 x 11%1且面小軟計数2 50 x 10%1 若在投手最後一個 Xofigo後回因,與即接受標準備還這些數(10):水核(2) - 現具有在佔無指於茲於副機會/從 繼續就公司应当標。

有危及骨髓功能證據(如先前接受細胞時性化學治療和/或放射治療)EBRT」之後的病人或晚期瀰變性浸潤到骨質(EOD4;superscan) 的細胞腺瘍病人、治療時體特別小心、在第11期試驗中,觀察到這些病人的血液學不良反應(例如增中性白血球減少症及血小板減少 症 發生率升高清整關策4級)。

克隆氏症與潰瘍性結腸炎

脊髓眶泊

在未治療面即將發生或已確認為脊髓壓迫的病人中,應於開始或重新開始Xofigo治療前依臨床所需完成標準照護治療

<u>骨折</u> 在骨折病人中,應於開始或重新開始Xofigo治療前完成骨折的骨科固定。

颚骨壤死

3012-3/1. 在接受雙磷酸膿類物與Xofigo治療的病人中,無法捐除有類骨壞死(ONJ)風險增加的情況。在第11期試驗中,Xofigo組曾有0.67%的 11度又交易的资源不均衡ACUEO的新加水了一部运动物的不同。在11%的分析和2000的原始不加加的形式一比如11%的磁带一ACUEO加出有10.07%的 第人(4600)通程ONI案例,相較於安曇創組則有0.33%的第人(1301)。然而,所有發生ONJ的婦人先前亦有使用或正併用變磷酸鹽 藥物(例如:zoleIronic acid)以及先前接受化學治療(例如:docetaxel)。

繼發性惡性腫瘤 Xofige會增加積人長期累積的整體放射線暴霧量。因此,長期累積的放射線暴霧可能與癌症及遺傳缺陷角風險增加具有相關性,尤 其是骨肉瘤、骨髓增生異常症候群及白血病的風險可能會增加。於臨床試驗中,長違3年的追蹤期間並無Xofige誘發痛症的案例通

程建動物試驗、Xofigo產生的放射線可能有造成生殖力不良反應的潛在風險(請參提第5.3單)。男性病人在治療前應尋求關於精子保 存的醫學建議。

又上EX版加强交全性概况是以第111期試驗中接受Xofge治療的60位从人資料作為基礎。接受Xofge治療的病人中最常體影到的不良 反應C10%為限制。吃A、%和及加小液減少症。而最廣重的不良反應附為加小液液少症及時中性自血均減少症清晰度第44期與後 透明。1%27年人民保護則1。2

<u>小長後認力法</u>
 公園会消佈中醫室到的不莫反應如「天浜不試着參閱表」)。這些不良反應為根據系統醫官類漸子以分類。使用最適當的MedDRA 詞彙
 以描述將定反應及其何資產和相關解況。
 臨床試驗中的不良反應進代表型生態率分類。每來定義如下:非常常見已 1/10)、常見2 1/10)至<1/10)、不常見2 1/100至<1/10)。
 在各級年載制約, 其不良支進為後繼重度邁越的關資將列。
 </p>

常見

(≥ 1/100到< 1/10)

嗜中性白血球减少症

全血球減少症

白血球減少症

注射部位反应

有1.2%接受Xofigo治療的病人以及0%接受安慰劑治療的病人,通報有第1和第2等級的注射部位反應,例如紅斑、疼痛及腫脹。

##221-2015/00/ml Xofigo會增加病人長期累積的整體放射線暴露量。長期累積的放射線暴露可能與癌症及遺傳缺陷的風險均加具有相關性,尤其是骨 肉瘤、骨髓增生显觉症候群及白血病的风险可能愈增加。於臨床試驗中,長達3年的追蹤期間並無Xafioa該滑稽症的案例通報 通報疑說不良反應 需較藥品即粉准後之通報疑似不良反應非常重要。此為能持續監測醫療藥品的效益/風險平衡。任何的疑似不良反應須通報至全國 藥物不反反應通報中心。

、2.2.3. 圖床試驗週間並無不值使用Xofigo過量的通報案例。Xofigo無特定解毒劑。不值使用過量時,應採取一般性的支持措施,包括監測 潛在的血液學及胃腸道毒性。

<u>電波変更来</u> 在一項第II開機後分配设施中, 研究5項管代術的点清生物構成(費利及構記: bone akaline phosphatase [ALP] · total ALP · procollagen IN properide [PINP] · 有吸或機能: C-terminal crosslinking telopeptide of type I collagen [S-CTX-I] · type I collagen crosslinked Celopeptide [ICP]) 病形X60gand 發行變感到正見前需差累。 <u>電波後最後全全地</u> 在一項質言、價值發化、多次劑量的茶III前多<u>中</u>-2%來試驗(ALSYMPCA)中, 對具有症及使增費棒移的去勢記述攝現線在病人進行

王安徽政部体为建筑存沛的"水安省特色活和现场基本等等,行(Ski)营业时以、加电ALP-QNA活(Suppl) 金融省電助令价值增量分削的背積成上即時,并采的防病人以2:1的比例植物完全基础会会利量频度注於Kofigo 55 kBaykg共后强运 综合係 建有能量数,定复新国等、北海社委、專業者、estamusineXketoconnzelo的代用。 在允许转换活像(市均投杂资源剂成為人社受Xofigo治费的機會)前,人有到21位通過为起病人完成安全は農整體存活期的最新放送性

本試驗捐除患有克隆氏症、溃疡性結腸炎、臟器轉移、先前接受半身性放射治療以及具有未處置之脊髓壓迫危險或確定為脊髓壓迫

在一次支出一個或方面、少以消量可加出的少子及協力或或(ALSTBICA)+一省有益於是有益的公司特別的方式。 Xofigo的關床交合性鼻腔支持体。這該場体除購選擇將及急性淋巴結病變超過3 cm的病人。 基礎放出標為整體存活期。次要指標包括出現有症狀骨結單件(SSE)發生時間、出現ALP及PSA毫化的时間。

中國政制的為「「人」「ALL」(當會」」和國家的個人一個目標等「人的國家」「外国家人又并且不過」(ALL)的的成人。 Xofigo及安慰劑兩組間的人口統計學與基期疾病特徵(期中分析族群)相似,下方為列出Xofigo組的資料

· 47%的痛人因不符音格克拒絕接受doceravel治療,而先前未接受doceravel治療

留住的血液学及自動這動任。 曾在一項第1期臨床試驗中評估過單劑量給予每公斤體重含有高速276 kBq放射活性的Xofigo劑量,並未觀察到任何劑量限制毒性。

不常見

(≥ 1/1.000到< 1/100)

淋巴球減少症

•16%的病人去骨轉移小於6處、44%的病人具有6至20處骨轉移,另40%的病人具有多於20處骨轉移或為超級影像(superscan)。

表2:第III期ALSYMPCA试验得到的存活结果

整體存活期中位数(月)(95% CI)

終機 应 活 即 中 位 粉 (月) (95% CI)

圖?:Kanlan.Meier整體森法曲線(期中分析)

0.1

0.6

0.5

0.4

0.3

0.2

0.1

0.0

Xofigo 541 Placebo 268 450 218 329 145 207 86 116 49 69 28 28 15

0.8 0.

0.6

0.5

0.3

lumber of patients at risk

圖3:Kaplan-Meier整體存活曲線(最新分析)

Xofigo銀74個月和安慰創組38個月)

87%の物へみへよ実置非常産症販売売合作加減(ECG)が差に整め支払の2.19。 42%の均為人具等費用を運動。 42%の均為人具等件管務人理系行管務人理総換をdocexaci注意。 42%の均為人具等, 支兵者成支配人業会ど常用支加機(加加)、12%の(1)人送執会を運動)、15%の(1)人送執会を運動)、15%の(1)人送執会を運動)、15%の(1)人送執会を運動)、15%の(1)人送執会を運動)、15%の(1)人送執会を運動)、15%の(1)人送執会を運動)、15%の(1)人送執会を運動)、15%の(1)、15% (1),15% (1),15%

Number of patients at risk

^b 危险比<1,以Xofigo转件;

期中分析

死亡数(%)

p值^a(登尾)

最新分析

死亡龄(%)

意 险 比^b (95% CF

危險比^b (95% CI)

播动余勤

在期中分析中,觀察到Xofigo加上最佳標準照護治療的OS中位教校安慰劍加上最佳標準照護治療增加2.8個月(HR = 0.695 (95%信頼

E同[CI]0.5520.875, +p=0.00185, •OS+位数; >分為為14.0億月秒11.2億月), 死亡風險降低更過的。 在最新分析寸,職業到久的國動上度使律無環境治療的整體存活劑中位款較妥認劑加上量佳權準團踐治療增加3.6億月[HR = 0.695 (95% <Cl.0.5810.0532), •OS+位数分為14.9億月升目1.3億月),</p>

Xofigo

N=541

191 (35.3%)

14.0(12.1 - 15.8)

N=614

149(139 - 161)

CI=信賴區間、HR=危險比(Xofigo相較於妄慰劑) 当期中分析後,即因療效因素而停止這項第III期試驗(ALSYMPCA)。由於最新分析僅為敘這性分析,因此並未提供p值

12 15 18

12 15

- Kofigo

---- Placebo

18 21 24 27

Time (m

Xofigo

期中分析与新分析的核果证置Xx0gat中标定主要次要误解描述的使空因消止达到新学校系有体专用直2-4450。 建设Xx0gacade的成人生在此达考察形队SET。C支展查生任何下方等件: 1X种用或体制的带走很有所有。在原现代形中、式甲链尿 違、或履输电器件科手術分小面衝慢走时可以接定空驾前活动的成人期等连续拥守分析: 1HL = 0.6610 9.9% CI 0.4610 9.0% SI 0.2520.350 SI SI 0.4610 9.0% SI 0.5200 9.0% SI 0.4610 9.0\% SI 0

施治店: 当营并截亡 国助动表达到 40 %). 6. 在地域 2. 公司的 40 从 47 % 2. 不动 2. 心动体的数据 42 % 2. 然前 42 % 2. 然前 42 % 2. 不动 42 % % 2. 不动 42 % 2. 不动 42 % 2. 不动 42 % 2. 不动 42 % 2.

Amgion3-ma/m-金属微量素化5.5mg/加速5.8m/为量量素的下降2_30%的病人百分比高於安慰剂血(物中分析:Xofigon46.2%,安慰剂加2.5%。 p=0.001:最新分析:Xofigon46.0%。安慰剂加3.5%)。 第12週刊XOfigon4年过到通2.LPC常化(定義為超大35%)。

Xofige 614 578 504 369 277 178 105 60 41 18 7 1 0 Plocebo 307 288 228 157 104 67 39 24 14 7 4 2 1

30 33 36

0.00185

0.695 (0.552 - 0.875)

0.695 (0.581 - 0.832)

24

安慰朝

N=268

123 (45.9%)

11.2(9.0 - 13.2)

N=307

195 (63 5%)

而近11. 依據給藥體積,本藥品每次劑量可能含有高違2.35 mmol (54 mg)的銷。對控制銷飲食的病人應考量到這點。

4.5 與其他藥品的交互作用,以及其他形式的交互作用

尚未進行臨床藥物交互作用的研究

不曾針對Xofigo進行動物內生殖研究。

4.7 對駕駛與操作機械能力的影響

系統器官類別

(MedDRA)

全身性疾患與給藥部位症狀

血小板減少症及嗜中性白血球減少症

血液與淋巴系統疾患

胃腸道疾患

特定不良反應說明

注射部位反应

编發性恶性网络

4.9 過量

5. 藥理特性

51藤分墨纬州

作用機轉

藥效學效果

生殖力 關於Xofigo對生殖力的影響,目前並無人體資料

並無證據及不預期Xofigo會影響駕駛或操作機械的能力。

表1:病人接受Xofigo治痨的臨床試驗中所通報的不良反應

藥物治療類別:各種治療用放射性藥物 ATC碼: V10XX03

 · 応人的平均年龄為70歳(協園49至90歳)。

男性避孕

懷孕與哺乳

4.8 不良反應

安全性概況摘要

不良反應到表

间不進口圖环來切交互作用的研究。 由於無法排除與鈣和磷酸的交互作用,應考慮於開始Xofigo治療前幾天起暫停使用這些物質和/或維生素D的補充劑。 Xofigo合併化學治療可能產生骨髓抑制的加成效果(請參閱第4.4節)。尚未確立Xofigo併用化學治療的安全性與療效。

由於有放射線對精子生成的潛在影響,應告知男性病人於Xofigo治療期間以及治療後6個月內使用有效的進孕方式。

16牛殖力、懷孕風醋到

非常常見

(≥ 1/10)

血小板減少症

腹瀉

嘔吐

嗯心

Xofigo不適用於女性病人。Xofigo不會用於已經懷孕、可能懷孕或正在哺乳的女性。

表3:ALSYMPCA試驗得到的沒要試驗指標:至症狀性骨骼事件時間(SSE)、至外照射旋射療法(EBRT)時間、至脊髓壓迫時間、至

	症炎性	计船事件			SSE構成事件						
	(SSE) ^a		以EBRT缓和疼痛		计链压迫		手折介	入治療	1	浙	
	Xofigo	安慰劑	Xofigo	安慰劑	Xofig	安慰劑	Xofig)	安慰劑	Xofigo	安慰劑	
駒中分析 (Xofigo担:N=54	位病人;安	慰劑组:N=	268位病人)						-		
發生率	132	82	122	72	117	16	9	5	20	18	
[病人数(%)]	(24.4%)	(30.6%)	(22.6%)	(26.9%)	(3.1%)	(6.0%)	(1.7%)	(1.9%)	(3.7%)	(6.7%)	
至事件時間分析 (95% CI)	13.5	8.4	17.0	10.8	NE	NE	NE	NE	NE	NE	
[中位數(月)]	(12.2-9.6)	(7.2 -NE ^d)	(12.9-NE)	(7.9-NE)							
p值 ^b (變尾)	0.0	0046	0.00375		0.01647		0.6	0.69041		0.01255	
HR ^e (95% CI)	0.6	510	0.649		0.443		0.801		0.450		
	(0.461	- 0.807)	(0.483 -	- 0.871)	(0.123 - 0.877) (0.167 - 2.398)		(0.236 - 0.856)				
最新分析 (Xofigo红:N=61	4位病人;安	慰劑组:N=	307位病人)								
發生率	201	116	186	105	25	21	12	7	32	20	
[病人數(%)]	(32.9%)	(37.8%)	(30.3%)	(34.2%)	(4.1%)	(6.8%)	(2.0%)	(2.3%)	(5.2%)	(65%)	
至事件時間分析 (95% CI)	15.6	9.8	17.1	17.5	NE	NE	NE	NE	NE	NE	
[中位數(月)]	(13.5-18.0)	(7.3 - 23.7)	(14.1 - 19.8)	$(7.8 - 29.0)^{\rm e}$							
HR ^e (95% CI)	0.6	58	0.6	70	0.5	16	0.1	715	0.620		
	(0.522	- 0.830)	(0.525 -	- 0.854)	(0.186-	- 0.931)	(0.180	-1.821)	(0.351	-1.093)	

CI=信賴區間, HBRT =外照納來射療法, HR =危險比(Xofigo相對於安慰劑) a SSEE 成為發生任何下方事件:以外照射放射療法提和疼痛,或病理性骨折,或脊髓壓迫,或距離相關骨科手術介入治療 的期令力將, 的因婚政因者所修止這項第III的讓缺入ISYMPCA, 自己是最份於僅為截退也分升,因此並表提供應值。 "期毕劳时候,可追控从国家时产还生用THITTANANA"(ALLANDANANA) 《ALLANDANANA》,即管并提出特点走到考虑起。 《思想清理》全面成人民的转载。 导致受惩刑组中EBRT事件较少,因而导致最新分析時至EBRT時間中位数较表的谈差。

考4:ALSVMPCA试验得到的注意试验指述:至她趋性磷酸酶(ALP)系化時間以及至前列度結晶化拉质(PSA)系化時間

	總ALP悉化*		PSA 是化 ^b		
	Xofigo	安慰劑	Xofigo	安慰劑	
期中分析 (Xofig)组:N=541在病	人;安慰劑組:N=268位	主病人)			
事件数	79 (14.6%)	116 (43.3%)	288 (51.2%)	141 (52.6%)	
急化時間(95% CI) [中位數(月)]	NE ^c	3.7 (3.5 - 4.1)	3.6 (3.5-3.7)	3.4 (3.3 - 3.5)	
p值 ^d (雙尾)	< 0.00001		0.00015		
危險比 ^e (95% Cl)	0.162 (0.120 - 0.220)		0.671 (0.546 - 0.826)		
最新分析 (Xofig)组:N=614在病	人;安慰劑組:N=307位	主病人)			
事件数	106 (17.3%)	151 (49.2%)	388 (6:.2%)	193 (62.9%)	
急化時間(95% CI) [中位教(月)]	7.4 (7.1 – NE ^f)	3.8 (3.6-42)	3.6 (3.5-3.8)	3.4 (3.3 - 3.5)	
危險比 ^e (95% Cl)	0.167 (0.129 - 0.217)		0.643 (0.539 - 0.768)		

NE:無法估算,即期中分析資外截止時尚未達到中位數。 期中分析後,時因療效因素而停止這項第III期試驗(ALSYMPCA)。由於最新分析僅為最進性分析,因此並未提供p值 e 危險比<1,以Xofigo較佳。 「NE: 無法估算,即因中位數後事件數不足。

表5:ALSYMPCA試驗得到的次要試驗指標:總鹼性磷酸酯(ALP)反應以及總ALP正常化

	第12週時的總ALP反應"		第12週時的總ALP正常化 ^b	
	Xofigo	安慰劑	Xofigo	安慰劑
期中分析 (Xofig>组:N=541在病。	人;安慰劑组:N=268位	病人)		
病人數(%)	176/381° (46.2)	4/160° (2.5)	83/252 ^d (32.9)	1/107 ^d (0.9)
p值 ^e (變尾)	< 0.001		< 0.001	
最新分析 (Xofig)组:N=614位病。	人;安慰劑維:N=307位	北病人)		
病人数(%)	233/497 ^c (46.9)	7/211° (3.3)	109/321 (34.0)	2/140 ^d (1.4)
定義為證實較基期下降≥30% 定義為基期時總ALP低高的病人其 同時具有基期時總ALP數值高的病人人 基期時總ALP數值高的病人及 期中分析後,即因療效因素而等止	的病人數		僅為敘述性分析,因此並非	t提供p值。

次群组存活分析 次群组存活分析结果顺示Xofigc治療具一致性的存活效益,而與基期時總給性導酸酶(ALP)数值、基期時雙導酸鹽藥物的使用,以及 先前使用docetaxel均無關

生活品質 一一一一。 在第III期ALSYMPCA試驗中使用特定問卷評估健康相關生活品質(HRQOL):EQ-5D (通用工具)以及FACT-P (前列線癌特定工具)。 基本III的ALSYARCA发展甲使時來之時是中時電機構施生活等(IHKQOL): EQOSI (這則工作)及其AKCIP([含)機構成+0.05) EOSD2時有荷利時素業置YAGG的高格是体與建構的時間KQOL或品素が完美術、可要支入為來在總長(IOHKRA)(II-10-0.05) 約克 現場現電量和定量很透電力(1)-10-0.05) 約克 現場現電量和定量素素(1)-10-0.05) 約克 現場現電量和定量素素(1)-10-0.05) 約克 現場電電量素素(1)-0.05) (1)-10-10-0.05) (1)-10-0.05 (1)-0.05 (1)-0.05 (1)-0.05 (1)-0.05 (1)-0.05 (1)-0.05 (1 麻捕植和

7/m∞→ 在第III期ALSYPMCA试验中,從發生需以體外放射線治療(EBRT)緩和疼痛的時間結果,以及較少通報骨頭疼痛的不良事件情形, 顯示Xofigo紅治發對骨頭疼痛有正面效果。 接着的細胞毒性物質治療

スオリールシーンスルムニン など:1該機分配ALSYMPCA试验進行期間,有93位(17%)Xofigo组病人及S4位(16.8%)安息劍組病人,在最後一次治療後的不同時間 接受知應毒性化學治療。南血病人間的血液學實驗室數值並無明顯差異。 5.2 藥動學特性

2026年 已從3項算開試矩得到簽勤勞、生物分佈及劑量學資料。簽勤學資料來自於使用劑量範圍分於51至276 kBq (0.00138至0.00746 mCi)kg 回約25位病人。養勤學、生物分佈及劑量學資料來自於6位接受問隔6週之2前110 kBq (0.00297 mCi)kg劑量的病人,以及10位決受55 (0.00149 mCi)、110 (0.00297 mCi)或221 kBq (0.00597 mCi)kg創量的病人。

Xofigo以静脈注着的方式给藥,因此達100%生體可用率

静脈注射後,鐺-223從血液中迅速排除且主要分佈進入骨頭及骨轉移病灶中,或排除到小腸中。 注射4小時後並未觀察到顏著的攝取量。

· 编-223是一種放射性同位素,會進行衰變而不會波代謝。

[編品將這體外的主來現起為農使經營。內有5%納除到基港中,且為非優排除的選擇,注約7天變份全會開資(總農雙校正能)顯示中位 數70%的設計就形式也說體每點像。備223二氟化物改胃勝道的結除進率,會受到不同族群的小腸傳輸進率高度變異地的影響, 正常範圍隊每天一式約局通一次的簡通總空。 線性/非線性

在研究的劑量活性範圍內(51至276 kBa/ka), 備-223二氯化物的藥動學為線性。

兒童族群 Xofigo於兒童和18並以下青少年的安全性與有效性尚未研究。

尚未在肝力能受損為人中進行過葉動學試驗。然而,由於緒-223作為一種同位素並不會被代謝,因此並不預期肝功能受損會影響氣 化緣-223的葉動學:

<u>臀功能受损病人</u> 7.7mx2m1---尚未在野功能受损或人中進行過藥動學試驗。然而,由於尿液排除極少而主要的清於路徑是透過糞便,因此並不預期野功能受損會 影響氣化緒-223的桑動學(請參閱「<u>用量用法</u>」一節)。 心臟電生理學/OT延長

在第III期試驗(ALSYMPCA)的一個29位病人的次組中(操受Xofigo治療的病人有21位,接受安慰耐治療的病人有8位),靜脈注射Xofigo6小時後並來觀察到相較於安慰劑的顯著QTc延長效果(即,>20ms)。

5.3 臨床前安全性資料 全身毒性

工业如心 在大战中进行的第一及量量积量查性试验中,主要保观高体整体加不足、血液学变化、血清给性导致的成少以及於显微镜中保观骨 锁注血血压脉动、强制带体力、弹头压强体扩展;作业品和骨型的常和肥。成常如肥、油膏加肥脉动、强带骨肤病止、生成加成长时的加速化的成长成功。 宽沉满)、主要使现象材料操作的适应加度含剂以完全生成成少有调,止在最低水时扩始将型呈贴和ykk的在建筑制量的4.4的产 始出现

在犬類試驗中,給子最低放射活性55kBq/kg(同臨床建議劑量)開始即觀察到血液學變化。在單次投予497kBq/kg的緒-223二氟化物/kg (臨床建議劑量的9份)後,在大類線察到劑量限制性骨髓毒性

(1997年後初1至1979)(2) 在人知他家中:197重[1997年19] 每4週重提投予同臨床建議之放射活性期量55 kBqKgi获g6個月後,2隻大類發生無位厚性骨當骨折,由於試驗動物在其他骨頭位置出 現不同程度的骨,每溶骨特別,為法排除是因溶骨造成自傳性骨折。這些發現的臨床相關站且前未知。

單次在大類注射設計活性積量166及497kBqkg(協康建議創量的3倍及9倍),觀察到我網際制備,但於每4週重複投予同臨床建議之故 新活性劑量55kBqkg試驗6個月後,則並未觀察到。將發現網躍刺離的確切機轉目首未知,但文獻資料顯示鑑會專門被攝取到大類 眼睛的照膜(tapetur lucidum)中。由於人類不具有照膜,因此無法判定這些發現對人體的臨床相關性。臨床試驗中並無視網膜剝維的 案例通報

并未在冬埠储-773二氧化物排除的器官中腹察到坦赫學變化。

工水化学开始222-3、100%市场75%10,10%产10%产74%10、20 在接受网路条相周滑量的大量中,试验网路免疫75212%用导地粮落到营汽瘤,这是据骨性放射性操难(bone-seeking radionuclide)的已却 不良反應。在大類式最中並未觀察到营汽瘤。X5figo的臨床試驗中亦無骨肉瘤的案例道框。暴露於縮-223的高人產生骨肉瘤的風險 目前未知。骨肉瘤以外的其他腫瘤變化,亦曾報導於大鼠的長期(12至15個月)毒性試驗中(請參閱第4.8節), 胚胎毒性/生殖毒性

商本針對生殖和發育臺佳進行試驗。一般而言,統新佳檢種認為會誘發生殖與發育試不良反應。 單次授予大於2270 (BqKg (2臨床建議劑量的41倍)的錨-223二氯化物後,在維健大氣睪丸中的少数面細精管中觀察到極少量異常的精 母細胞。除此之外,睪丸功能看似正常,且副睪中的精母細胞数量正常。單次或重複投予大於359 kBq/kg的錫-223二氟化物(≥臨床建 通利量的6.5倍)後,在雌性大鼠中觀察到子宫息肉(子宫內膜間質)。

由於經-273主要分行在骨頭,始患有去势抗性攝護障碍的病症病人,某發生累性性質不良反應的潛在風險非常低,但無法插除(清条 閲第4.6節) 基因毒性/致癌性

同来針對Xofigo的致突變性和致癌可能性進行試驗。一般而言,放射性核種都被視為具有基因毒性和致癌性。

容全碰理墨 《二水二·1 單次投予放射活性劑量介於497至1100 kBq/kg (臨床建議劑量的9倍[火類]至20倍[大氯])的鎬-223二氧化物,並未觀察到重要器官系統 (即亦心血管[犬類],呼吸或中樞神經系統[大鼠])的重大不良反應

蔥劑特性 | 赋形剂 化纳 15 10 44 氯酸(稀释) 2不相容性 於缺乏相容性研究,本藥品不得與其他藥品混合

3保存期限

(儲存特殊注意事項

藥品請儲存於 40°C以下

Xofigo應依照國內對於放射活性物質的規定進行儲存。 6.5 容器性質與內容物

本藥品包浆為包覆有乙烯-四氟乙烯(ETFE)的灰色溴化丁基橡膠瓶塞及銘箔封口的無色第1顆玻璃藥瓶,含有6mL的注射用溶液 施和治胃於铝罐中

6.6 素置與其他處理的特殊注意事項 一般警语

應只經由合格人員於專門指定的臨床場所收取、使用及給予放射性藥物。其收取、借存、使用、移轉及委置均應遵照政府主管機關 的相常和/或即旗演李体可

Xofigo的使用方式為同時符合放射安全及藥物品質規定。應採取適當的無菌預防措施。 放射線防護

编-273及其子代(dauphters)於袁變侍產生的v放射線,得以運用標準循蓋來測量Xofien的放射活性,以及偵測放射污染。 任何未使用的藥品或廢棄物質之業置均應依照當地規定。

繁优去绘予Xofigo请程中使用的任何物質,均度观為放射性麻蚕物

7. 放射線劑量

吸收放射接的制量为依接脑床生物分佈管料计算,其吸收制量的計算為使用OLINDA/FXM (器官層級內部制量評估/指數線型IOrea Level Niema DoseAssessmert/Exponentia Modeling),这是以勞用當份和希謝受(MRD)演算法為基礎的一個軟體;其產品於常規 使用的β.Dyr放射性魚種中。針對露-223而言,由於其主要為α粒子放射體,因此針對小腸、紅骨髓及骨頭/成骨細胞作出額外假設。 並考處其觀察到的生物分佈與特殊性質,計算出Xofigo治療中最可能的吸收劑量(請參閱表6)

表6:計算器官吸收的放射線劑量

	Alpha ¹	Beta emission	Gamma	Total dose	Total dose	Coefficient of	
Target Organ	emission	(Gy/MBq)	emission (Gy/MBq)	(Gy/MBq)	(rad/mCi)	variation	
	(Cy/MBq)					(%)	
Adrenals	(.00000	0.00002	0.00009	0.00012	0.44	56	
Brain	(.00000	0.00002	0.00008	0.00010	0.37	80	
Breasts	(.00000	0.00002	0.00003	0.00005	0.18	120	
Gallbladder wall	(.00000	0.00002	0.00021	0.00023	0.85	14	
LLI ² Wall	(.00000	0.04561	0.00085	0.04545	171.88	83	
Small intestine wall	(.00319	0.00360	0.00047	0.00726	26.87	45	
Stomach wall	(.00000	0.00002	0.00011	0.00014	0.51	22	
ULI ³ wall	(.00000	0.03149	0.00082	0.03232	119.58	50	
Heart wall	(.00161	0.00007	0.00005	0.00173	6.40	42	
Kidneys	(.00299	0.00011	0.00011	0.00321	11.86	36	
Liver	(.00279	0.00010	0.00008	0.00298	11.01	36	
Lungs	(.00109	0.00007	0.00005	0.00121	4.47	4	
Muscle	(.00000	0.00002	0.00010	0.00012	0.44	41	
Ovaries	(.00000	0.00002	0.00046	0.00049	1.80	40	
Pancreas	(.00000	0.00002	0.00009	0.00011	0.41	43	
Red marrow	(.13217	0.00642	0.00020	0.13879	513.51	41	
Ostecgenic cells	1.13689	0.01487	0.00030	1.15206	4262.60	41	
Skin	(.00000	0.00002	0.00005	0.00307	0.27	79	
Spleen	(.00000	0.00002	0.00007	0.00009	0.33	54	
Testes	(.00000	0.00002	0.00006	0.00308	0.31	59	
Thymus	(.00000	0.00002	0.00003	0.00306	0.21	109	
Thyroid	(.00000	0.00002	0.00005	0.00307	0.27	96	
Urinary bladder wall	(.00371	0.00016	0.00016	0.00403	14.90	63	
Uterus	(.00000	0.00002	0.00023	0.00026	0.94	28	
Whole body	(.02220	0.00081	0.00012	0.02312	85.56	16	

由於在大部分的數組織中者並未觀察到儲-223吸收,因此設定這些器官中(n新線佔總器官制量的比例為0。 ²LLI:下段大腸 ³ULI:上段大腸

4 肺臟吸收劑量資料乃是使用所有受試者中合併血液時間-活性資料,以非型導出的計算為準

在Xofigo臨床該驗中觀察到的血液學不良反應頻率及展重度,這該於從計算出的紅背體吸收劑量下的預期情況。這可能與at粒子放射 線的空間分佈造成紅骨觸接空到非均匀的或射線劑量有關。

8. 放射性藥物製備說明

(An Allan Angle Tulky 2、 Sofigo為澄清無色溶液,若變色、出現類執非質或色裝成損即不應使用。 Sofigo為即用型溶液,不應修釋或與任何溶液混合。 專個難成僅是求及使用。

應使用以下資料計算特定病人的注射給藥體積:

·病人體重(公斤) · 劑量標準(55 kBq/公斤體重)

- 期重都年(155KB(267)短里) - 藥品券委照日期時的放射續活性濃度(1100 kBq/mL)。拿照日期播於藥成及鉛罐接截上。 - 鑄之251 族衰變之衰變校成正DK)因子。衰變校正表提供如下(请李問表5)。 給藥體積中的放射活性含量應使用正確校準的活性測量儀確認。

病人注射的给藥總體積計算方式如下:

DK 图子×1100 kBa/m

任何未使用的藥品或廢棄物質之業置均應依照當地規定

表7:鐺223的衰變校正因子炎 自参照日期起的天数 自参照日期起的天数

-14	2.38	0	1.02
-13	2.24	1	0.96
-12	2.11	2	0.90
-11	1.98	3	0.85
-10	1.87	4	0.80
-9	1.76	5	0.75
-8	1.65	6	0.71
-7	1.56	7	0.67
-6	1.46	8	0.63
-5	1.38	9	0.59
-4	1.30	10	0.56
-3	1.22	11	0.52
-2	1.15	12	0.49
-1	1.08	13	0.46
		14	0.44

製造廠: Institute for Energy Technology 廠 址: Instituttveien 18, NO-2007 Kjeller, Norway 藥 商:合灣并平成分有限公司

挂:台北市信盖路五段7號54樓

電 話:(02) 8101-1000 版本:EU SmPC / CCDS05 / TW03

Bayer

衰變因子